首页 | 本学科首页   官方微博 | 高级检索  
     


Tetraploidy and 5q deletion in myelodysplastic syndrome: a case report
Authors:Znoyko Iya  Stuart Robert K  Ellingham Tara  Winters Jennifer  Wolff Daynna J  Quigley Denise I
Affiliation:

aDepartment of Pathology and Laboratory Medicine, Medical University of South Carolina, 165 Ashley Ave, Ste. 309, Charleston, SC 29425

bDepartment of Hematology and Oncology, Medical University of South Carolina, 165 Ashley Ave, Ste. 309, Charleston, SC 29425

cPathology Sciences Medical Group, Sentara Laboratory Services, Norfolk, VA 23510

Abstract:Tetraploidy is a very rare cytogenetic abnormality in myelocytic malignancies, and its significance is unclear to date. We report here on a 68-year-old male diagnosed with myelodysplastic syndrome/refractory anemia with excess blasts (MDS/RAEB). Cytogenetic analysis of his bone marrow biopsy at initial clinical presentation and in subsequent studies revealed the presence of two abnormal clones, 92,XXYY and 92,XXYY,del(5)(q13q33). Interphase fluorescence in situ hybridization analysis of abnormal cells confirmed interstitial deletion in 5q, demonstrated predominance of the tetraploid clone and persistent presence of the tetraploid clone with 5q deletion. The patient was not responsive to Revlimid (lenalidomide) treatment, which is routinely used in patients with 5q– syndrome. However, a subsequent course of therapy with the methyl-transferase inhibitor decitabine resulted in clinical and cytogenetic remission. Our data suggest that the unique complex abnormality of tetraploidy and 5q deletion described here for the first time in MDS is characterized by distinct disease etiology, the mechanism of which could involve epigenetic inactivation of gene expression via methylation. ©2008 Elsevier Inc. All rights reserved.
Keywords:
本文献已被 ScienceDirect PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号